Precise diagnosis of disease and developmental syndromes often depends on understanding the genetics underlying them. Most cases of early onset hearing loss are genetic in origin but there are many different forms. Heretofore, it has been difficult to identify the gene responsible for the hearing loss of each affected child,...
Read more
Blog
Andromeda: Successful Phase III Diabetes Trial
Andromeda Biotech Ltd. announced initial results from a pivotal phase III clinical study. The 24-month study was randomized, placebo-controlled, designed to assess the safety and efficacy of DiaPep277®, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with Type 1 Diabetes (T1D). The results from patients who were...
Read more
BioLineRx Phase III in India
BioLineRx (NASDAQ:BLRX) (TASE:BLRX) has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. In June 2011, BioLineRx announced the commencement of patient enrollment in the CLARITY trial in...
Read more
GE Orders WideMed Sleep Monitor
WideMed (WDMD) Ltd. has received orders for its home sleep monitoring device Morpheus HX systems from GE Healthcare for the Canadian and Korean markets. The device was cleared for marketing to cardiac patients in the US by the FDA in September. s WideMed’s portable home sleep diagnostic and monitoring watch-size...
Read more
Avraham Raises $3 M for Neuro
Avraham Pharmaceuticals has raised $3 million from Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others. This investment round follows a U.S. $9 million financing in April, 2010. Avraham...
Read more